No Data
No Data
Context Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025
JMP Securities Maintains Context Therapeutics(CNTX.US) With Buy Rating, Maintains Target Price $4
Strategic Advancements and Financial Health Propel Context Therapeutics to a 'Buy' Rating
Companies Like Context Therapeutics (NASDAQ:CNTX) Are In A Position To Invest In Growth
H.C. Wainwright Maintains Context Therapeutics(CNTX.US) With Buy Rating, Maintains Target Price $5
Piper Sandler Maintains Context Therapeutics(CNTX.US) With Buy Rating, Maintains Target Price $4.5